Fenwick Represents Lemonaid Health in Definitive Agreement to Be Acquired by 23andMe

Fenwick represented Lemonaid Health, Inc., an on-demand platform for accessing medical care and pharmacy services online, in its definitive agreement to be acquired by 23andMe Holding Co. (Nasdaq: ME) for a purchase price of $400 million.

The acquisition adds Lemonaid Health’s innovative telemedicine and prescription drug delivery services to 23andMe’s consumer business. More information can be obtained from 23andMe’s announcement.

The Fenwick transaction team was led by corporate partners David Healy and Matthew Rossiter and included associates Janiece Jenkins, Meredith Evancie, Ugo Nwasike and Tim Wilson; executive compensation and employee benefits partner Marshall Mort, counsel Jane Piehler and associates Corinne Nhaissi, Christophe Delrieu and Cynthia Yuan; technology transactions counsel Christopher Joslyn and associate Andrew Martinez; and tax partner Julia Ushakova-Stein and associate Alexis Maguina.